? Cells are comprised of many types of molecules, including small organic and inorganic molecules, carbohydrates, lipids, proteins, and nucleic acids. All of these molecules act in an integrated fashion at the molecular level to result in macroscopic cellular, tissue, and systemic phenotypes. Complete understanding of biological function would require accurate measurement of all of these molecules simultaneously. Vlicroarrays have made it possible to analyze nucleic acids at the genome-scale, but techniques for other cellular molecules currently lag behind. With proteins as another class of molecules prominent in cellular function and communication, intense effort is being invested toward the development and implementation of proteomic strategies for the analysis of clinical and research samples. Current proteomic strategies take many forms but can be grossly categorized as either array-based or not. Multiple array-based strategies nave been developed based on antibody recognition of the proteins of interest. The use of antibodies, however, brings with it issues of reproducible antibody production, target binding affinity, and denaturation. It is proposed to develop a strategy by which cancer signatures can be established by measuring protein concentrations in an array-based proteomic technology using aptamers, protein-binding RNA molecules. To ensure that the method can be expanded to parallel studies, each aptamer will be labeled with a molecular barcode. The protein concentration will then be obtained by measuring the concentration of the barcode on the aptamer that binds specifically to that protein. The method will be tested on a cell-culture model of Type 2 diabetes, providing valuable data for technique development as well as an improved understanding of the response of the liver to inflammatory stresses. Aptamers will be used for solution phase measurement of acute phase proteins as a preliminary demonstration of the possibility of future implementation of the strategy in a microarray format.
The specific aims of the proposed work are to: i) generate molecular barcode-containing, structure-switching aptamers by in vitro selection and identify conserved sequence and structural features; ii) quantify the affinities and association kinetics of aptamertarget protein binding interactions; and iii) measure the acute phase protein expression profile of stimulated rat hepatocytes in cell- culture using the molecular barcode-containing aptamer strategy. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA126136-02
Application #
7295800
Study Section
Special Emphasis Panel (ZCA1-SRRB-9 (O1))
Program Officer
Rodriguez, Henry
Project Start
2006-09-27
Project End
2009-08-31
Budget Start
2007-09-01
Budget End
2009-08-31
Support Year
2
Fiscal Year
2007
Total Cost
$157,357
Indirect Cost
Name
Michigan State University
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
193247145
City
East Lansing
State
MI
Country
United States
Zip Code
48824
Xie, Shengnan; Walton, S Patrick (2010) Development of a dual-aptamer-based multiplex protein biosensor. Biosens Bioelectron 25:2663-8
Gredell, Joseph A; Dittmer, Michael J; Wu, Ming et al. (2010) Recognition of siRNA asymmetry by TAR RNA binding protein. Biochemistry 49:3148-55
Zhang, Linxia; Seitz, Linsey C; Abramczyk, Amy M et al. (2010) Synergistic effect of cAMP and palmitate in promoting altered mitochondrial function and cell death in HepG2 cells. Exp Cell Res 316:716-27
Yang, Xuerui; Nath, Aritro; Opperman, Michael J et al. (2010) The double-stranded RNA-dependent protein kinase differentially regulates insulin receptor substrates 1 and 2 in HepG2 cells. Mol Biol Cell 21:3449-58
Dalkic, Ertugrul; Wang, Xuewei; Wright, Neil et al. (2010) Cancer-drug associations: a complex system. PLoS One 5:e10031
Xie, Shengnan; Moya, Colby; Bilgin, Betul et al. (2009) Emerging affinity-based techniques in proteomics. Expert Rev Proteomics 6:573-83
Kini, Hemant K; Walton, S P (2009) Effect of siRNA terminal mismatches on TRBP and Dicer binding and silencing efficacy. FEBS J 276:6576-85
Xie, Shengnan; Walton, S Patrick (2009) Application and analysis of structure-switching aptamers for small molecule quantification. Anal Chim Acta 638:213-9
Li, Zheng; Chan, Christina (2009) Systems biology for identifying liver toxicity pathways. BMC Proc 3 Suppl 2:S2
Dalkic, Ertugrul; Nash, Daniel Elwin Walter; Fassia, Mohammad Kasim et al. (2009) Integrative analysis of cancer pathway progression and coherence. Proteomics Clin Appl 3:473-85

Showing the most recent 10 out of 21 publications